Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Free Cash Flow (2016 - 2025)

Ptc Therapeutics has reported Free Cash Flow over the past 14 years, most recently at -$36.6 million for Q4 2025.

  • Quarterly results put Free Cash Flow at -$36.6 million for Q4 2025, down 34.05% from a year ago — trailing twelve months through Dec 2025 was $702.3 million (up 751.77% YoY), and the annual figure for FY2025 was $702.3 million, up 751.77%.
  • Free Cash Flow for Q4 2025 was -$36.6 million at Ptc Therapeutics, up from -$69.7 million in the prior quarter.
  • Over the last five years, Free Cash Flow for PTCT hit a ceiling of $868.4 million in Q1 2025 and a floor of -$174.6 million in Q4 2022.
  • Median Free Cash Flow over the past 5 years was -$58.3 million (2021), compared with a mean of -$13.0 million.
  • Biggest five-year swings in Free Cash Flow: plummeted 344.25% in 2021 and later skyrocketed 1319.55% in 2025.
  • Ptc Therapeutics' Free Cash Flow stood at -$77.6 million in 2021, then crashed by 125.08% to -$174.6 million in 2022, then surged by 39.37% to -$105.9 million in 2023, then skyrocketed by 74.17% to -$27.3 million in 2024, then crashed by 34.05% to -$36.6 million in 2025.
  • The last three reported values for Free Cash Flow were -$36.6 million (Q4 2025), -$69.7 million (Q3 2025), and -$59.6 million (Q2 2025) per Business Quant data.